SCHEMBL1406867

SCHEMBL1406867

CC(C)N1CCN(c2cc(C(=O)/C=C/c3ccc(C(=O)O)c(O)c3)cc3c2C(C)(C)CCC3(C)C)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 3/20 0.36
RARG P13631 2/20 0.36
RARA P10276 1/20 0.36
CYP26A1 O43174 1/20 0.36
RXRA P19793 4/20 0.36
PTPN1 P18031 1/20 0.35
DHODH Q02127 1/20 0.35
CTSL P07711 1/20 0.33
CTSB P07858 1/20 0.33
APP P05067 1/20 0.33
RXRB P28702 1/20 0.33
RXRG P48443 1/20 0.33
HDAC6 Q9UBN7 2/20 0.33
MEN1 O00255 1/20 0.33
EGFR P00533 1/20 0.33
SRC P12931 1/20 0.33
AKR1B1 P15121 1/20 0.33
NFKB1 P19838 1/20 0.33
CDK2 P24941 1/20 0.33
HSD17B2 P37059 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1406870 1.00 RARB (0.36) RARBRARGRARACYP26A1RXRA
SCHEMBL1406430 0.95 RARB (0.35) RARBRARGRARACYP26A1RXRA
SCHEMBL1406340 0.90 HDAC3 (0.41) RARBRARGRARACYP26A1RXRA
SCHEMBL1406337 0.90 HDAC3 (0.41) RARBRARGRARACYP26A1RXRA
SCHEMBL6420593 0.89 RARA (0.33) RARBRARGRARA
SCHEMBL1406261 0.88 RARB (0.46) RARBRARGRARACYP26A1RXRA
SCHEMBL1406260 0.88 RARB (0.46) RARBRARGRARACYP26A1RXRA
SCHEMBL1406432 0.86 MAOB (0.35) RARBRARGRARACYP26A1RXRA
SCHEMBL1406431 0.86 MAOB (0.35) RARBRARGRARACYP26A1RXRA
SCHEMBL6420607 0.85 RARA (0.37) RARBRARGRARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513793-B1 NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2011-03-09 EP claimed
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 US claimed
EP-1513793-B1 NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2011-03-09 EP disclosed
US-7468457-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-23 US disclosed
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG RARB 2/4885RARG 3/4885RARA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.